G. Krivoborodov, N. S. Efremov, D. A. Shirin, A. A. Gontar, O. N. Tkacheva
{"title":"Uroselective α1A-Adrenoceptor Antagonist Tamsulosin in Treatment Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia","authors":"G. Krivoborodov, N. S. Efremov, D. A. Shirin, A. A. Gontar, O. N. Tkacheva","doi":"10.37586/2686-8636-4-2023-295-300","DOIUrl":null,"url":null,"abstract":"Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) is a common condition in older man. Uroselective a1a-adrenoceptor (AR) antagonists tamsulosin and tamsulosin modified release (OCAS) are the most frequently prescribed medications for the men with LUTS due to BPH. Both tamsulosin and tamsulosin OCAS improve the patients disease-specific quality of life, reduce IPSS by approximately 30–40% and increase Qmax by approximately 20– 25%. The high selectivity of tamsulosin to α1А-adrenoceptor and slow release system OCAS provide a minimal vasodilating effect and correspondingly low risks of falls. These benefits are important in the treatment of LUTS in older men.","PeriodicalId":256357,"journal":{"name":"Russian Journal of Geriatric Medicine","volume":"44 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Geriatric Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37586/2686-8636-4-2023-295-300","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) is a common condition in older man. Uroselective a1a-adrenoceptor (AR) antagonists tamsulosin and tamsulosin modified release (OCAS) are the most frequently prescribed medications for the men with LUTS due to BPH. Both tamsulosin and tamsulosin OCAS improve the patients disease-specific quality of life, reduce IPSS by approximately 30–40% and increase Qmax by approximately 20– 25%. The high selectivity of tamsulosin to α1А-adrenoceptor and slow release system OCAS provide a minimal vasodilating effect and correspondingly low risks of falls. These benefits are important in the treatment of LUTS in older men.